Prostate Cancer Foundation Announces Collaborative Research Grants Program
Posted: Tuesday, October 15, 2019
The Prostate Cancer Foundation (PCF) recently announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through a Competitive Research Grants Program, which is focused on investigating the use of the PARP inhibitor talazoparib in prostate cancer. This is the first research funding collaboration between the two organizations.
“We are honored to partner with Pfizer to help support our critical mission of identifying and supporting impactful research that will improve the lives of men diagnosed with prostate cancer. PCF funded the seminal discoveries surrounding the role of PARP in prostate cancer, and its potential as a precision medicine target in patients with advanced disease. We are highly enthusiastic about the new grants program, which will support new clinical research for talazoparib in prostate cancer and lead to improved understanding about which patients may benefit from this treatment,” said Howard Soule, PhD, Executive Vice President and Chief Science Officer of the Prostate Cancer Foundation.
Through this funding mechanism, the Prostate Cancer Foundation and Pfizer will support approximately three innovative clinical investigations or clinical trial correlative research studies surrounding the use of talazoparib in prostate cancer. Applications will be peer-reviewed by an independent review panel composed of expert academic researchers to select the most impactful studies for funding. The amount of each award will be determined based on the external review panel’s evaluation of each project, and investigators in all countries and geographic regions are invited to apply.
To review the request for proposals, visit https://www.pcf.org/science-impact/for-researchers/open-rfas/.
